We would like to welcome you to join the PDA Virus Conference 2024 to be held on 26-27 June 2024 in Amsterdam, The Netherlands.

The Implementation of the newly published ICH Q5A into practice is a topic that all of the biopharmaceutical industry is eagerly discussing. Four main areas have been significantly updated in the new revision which has a major impact on the viral safety strategies for biological products. The revision expands the possibility of using prior knowledge for validation of viral clearance. The scope of the new ICH Q5A has been extended to cover new, advanced therapy, product types such as certain viral vectors (along with their helper viruses used at vector production). The implementation of virus safety principles in continuous manufacturing processes highlights a number of unique challenges which are discussed in new chapters of the guideline. One of the most significant changes in the new revision is the acknowledgment and implementation of advanced technologies such as next-generation sequencing and PCR for virus detection and the potential use of these technologies for replacing commonly used in vivo and in vitro adventitious agent tests.

Event Link here.